Patents by Inventor John Walter Liebeschuetz

John Walter Liebeschuetz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PYRAZOLO[3,4-B]PYRAZINE SHP2 PHOSPHATASE INHIBITORS
    Publication number: 20230049719
    Abstract: The invention provides new pyrazine derivatives of formula (I): or a tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined herein. The invention also provides pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Application
    Filed: August 20, 2020
    Publication date: February 16, 2023
    Applicants: OTSUKA PHARMACEUTICAL CO., LTD., TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Steven HOWARD, John Walter LIEBESCHUETZ, Tadashi SHIMAMURA
  • HETEROBICYCLIC COMPOUNDS FOR INHIBITING THE ACTIVITY OF SHP2
    Publication number: 20220363693
    Abstract: A compound of formula (I): wherein Ring A, Q, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, X, a, b, c and d are as defined in the specification.
    Type: Application
    Filed: July 23, 2019
    Publication date: November 17, 2022
    Applicants: TAIHO PHARMACEUTICAL CO., LTD., OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Tadashi SHIMAMURA, Ryo KATO, Risako MIURA, Takashi MITA, Takahiro OGAWA, Yufu SAGARA, Christopher Norbert JOHNSON, Steven HOWARD, James Edward Harvey DAY, Jeffrey David ST. DENIS, John Walter LIEBESCHUETZ
  • Pharmaceutical compounds
    Patent number: 11466016
    Abstract: The invention provides new pyrazine derivatives of formula (I): or a tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined herein. The invention also provides pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: October 11, 2022
    Assignees: OTSUKA PHARMACEUTICAL CO., LTD., TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Christopher Norbert Johnson, Ildiko Maria Buck, Gianni Chessari, James Edward Harvey Day, Hideto Fujiwara, Christopher Charles Frederick Hamlett, Steven Douglas Hiscock, Rhian Sara Holvey, Steven Howard, John Walter Liebeschuetz, Nicholas John Palmer, Jeffrey David St Denis, David Geoffrey Twigg, Andrew James Woodhead
  • PHARMACEUTICAL COMPOUNDS
    Publication number: 20210107908
    Abstract: The invention provides new pyrazine derivatives of formula (I): or a tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined herein. The invention also provides pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Application
    Filed: March 1, 2019
    Publication date: April 15, 2021
    Applicants: OTSUKA PHARMACEUTICAL CO., LTD., TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Christopher Norbert JOHNSON, Ildiko Maria BUCK, Gianni CHESSARI, James Edward Harvey DAY, Hideto FUJIWARA, Christopher Charles Frederick HAMLETT, Steven Douglas HISCOCK, Rhian Sara HOLVEY, Steven HOWARD, John Walter LIEBESCHUETZ, Nicholas John PALMER, Jeffrey David ST DENIS, David Geoffrey TWIGG, Andrew James WOODHEAD
  • Meta-benzamidine derivatives as serine protease inhibitors
    Patent number: 7928137
    Abstract: Compounds of formula I in which R1, R2, R3, each X, L, Y, Cy, Lp, D and n have the meanings as set out in the specification, and corresponding compounds in which the unsubstituted or substituted amidine group is replaced with an unsubstituted or substituted aminomethyl group, are useful as serine protease inhibitors.
    Type: Grant
    Filed: March 2, 2007
    Date of Patent: April 19, 2011
    Assignee: Tularik Limited
    Inventors: John Walter Liebeschuetz, William Alexander Wylie, Bohdan Waszkowycz, Christopher William Murray, Andrew David Rimmer, Pauline Mary Welsh, Stuart Donald Jones, Jonathan Michael Ernest Roscoe, Stephen Clinton Young, Phillip John Morgan
  • Factor Xa inhibitors
    Patent number: 7427632
    Abstract: Compounds of formula (I) in which R1, n, Z, R3 and R4 have any of the meanings given in the specification, are inhibitors of the serine protease Factor Xa and are useful in the treatment of thrombotic disorders.
    Type: Grant
    Filed: December 22, 2003
    Date of Patent: September 23, 2008
    Assignee: Eli Lilly and Company
    Inventors: Scott Martin Sheehan, Brian Morgan Watson, John Walter Liebeschuetz
  • Serine protease inhibitors
    Patent number: 7351822
    Abstract: Compounds of formula (I) in which R2, X, Y, Cy, L and Lp(D)n have the meanings given in the specification, are inhibitors of the serine protease, Factor Xa and are useful in the treatment of cardiovascular disorders.
    Type: Grant
    Filed: March 18, 2004
    Date of Patent: April 1, 2008
    Assignee: Eli Lilly and Company
    Inventors: John Walter Liebeschuetz, Christopher William Murray, Stephen Clinton Young, Nicholas Paul Camp, Stuart Donald Jones, William Alexander Wylie, John Joseph Masters, Michael Robert Wiley, Scott Martin Sheehan, David Birenbaum Engel, Brian Morgan Watson, Peter Robert Guzzo, Michael John Mayer
  • Chemical compounds
    Patent number: 7265121
    Abstract: Compounds of formula (I) in which R1, R2 and X4 have the meanings given in the specification are Factor Xa inhibitors useful in the treatment of thrombotic disorders.
    Type: Grant
    Filed: July 24, 2002
    Date of Patent: September 4, 2007
    Assignee: Eli Lilly and Company
    Inventors: Michael Robert Wiley, Daniel Jon Sall, John Walter Liebeschuetz
  • Meta-benzamidine derivatives as serine protease inhibitors
    Patent number: 7220781
    Abstract: Compounds of formula I in which R1, R2, R3, each X, L, Y, Cy, Lp, D and n have the meanings as set out in the specification, and corresponding compounds in which the unsubstituted or substituted amidine group is replaced with an unsubstituted or substituted aminomethyl group, are useful as serine protease inhibitors.
    Type: Grant
    Filed: January 8, 2004
    Date of Patent: May 22, 2007
    Assignee: Tularik Limited
    Inventors: John Walter Liebeschuetz, William Alexander Wylie, Bohdan Waszkowycz, Christopher William Murray, Andrew David Rimmer, Pauline Mary Welsh, Stuart Donald Jones, Jonathan Michael Ernest Roscoe, Stephen Clinton Young, Phillip John Morgan
  • Serine protease inhibitors
    Patent number: 7053078
    Abstract: Compounds of formula (I) in which R2, X, Y, Cy, L and Lp(D)n have the meanings given in the specification, are inhibitors of the serine protease, Factor Xa and are useful in the treatment of cardiovascular disorders.
    Type: Grant
    Filed: June 12, 2001
    Date of Patent: May 30, 2006
    Assignee: Eli Lilly and Company
    Inventors: John Walter Liebeschuetz, Christopher William Murray, Stephen Clinton Young, Nicholas Paul Camp, Stuart Donald Jones, William Alexander Wylie, John Joseph Masters, Michael Robert Wiley, Scott Martin Sheehan, David Birenbaum Engel, Brian Morgan Watson
  • Serine protease inhibitors
    Patent number: 6946467
    Abstract: The compound 1-(indole-6-carbonyl-D-phenylglycinyl)-4-(1-methylpiperidin-4-yl)piperazine and physiologically-tolerable salts thereof are factor Xa inhibitors useful for the treatment of thrombotic disorders.
    Type: Grant
    Filed: December 6, 2001
    Date of Patent: September 20, 2005
    Assignee: Eli Lilly and Company
    Inventors: John Walter Liebeschuetz, Christopher William Murray, Stephen Clinton Young, Nicholas Paul Camp, Stuart Donald Jones, William Alexander Wylie, John Joseph Masters, Michael Robert Wiley, Scott Martin Sheehan, David Birenbaum Engel, Brian Morgan Watson, Peter Robert Guzzo, Michael John Mayer
  • Serine protease inhibitors
    Patent number: 6936611
    Abstract: Compounds of formula (I) in which R2, X, Y, Cy, L and Lp(D)n have the meanings given in the specification, are inhibitors of the serine protease, Factor Xa and are useful in the treatment of cardiovascular disorders.
    Type: Grant
    Filed: January 12, 2004
    Date of Patent: August 30, 2005
    Assignee: Eli Lilly and Company
    Inventors: John Walter Liebeschuetz, Christopher William Murray, Stephen Clinton Young, Nicholas Paul Camp, Stuart Donald Jones, William Alexander Wylie, John Joseph Masters, Michael Robert Wiley, Scott Martin Sheehan, David Birenbaum Engel, Brian Morgan Watson, Peter Robert Guzzo, Michael John Mayer
  • Serine protease inhibitors
    Patent number: 6900196
    Abstract: Compounds of formula (I) in which R2, X, Y, Cy, L and Lp(D)n have the meanings given in the specification, are inhibitors of the serine protease, Factor Xa and are useful in the treatment of cardiovascular disorders.
    Type: Grant
    Filed: July 6, 2004
    Date of Patent: May 31, 2005
    Assignee: Eli Lilly and Company
    Inventors: John Walter Liebeschuetz, Christopher William Murray, Stephen Clinton Young, Nicholas Paul Camp, Stuart Donald Jones, William Alexander Wylie, John Joseph Masters, Michael Robert Wiley, Scott Martin Sheehan, David Birenbaum Engel, Brian Morgan Watson
  • Serine protease inhibitors
    Patent number: 6878725
    Abstract: Compounds of formula (I) in which R2, X, Y, Cy, L and Lp(D)n have the meanings given in the specification, are inhibitors of the serine protease, Factor Xa and are useful in the treatment of cardiovascular disorders.
    Type: Grant
    Filed: June 12, 2001
    Date of Patent: April 12, 2005
    Assignee: Eli Lilly and Company
    Inventors: John Walter Liebeschuetz, Christopher William Murray, Stephen Clinton Young, Nicholas Paul Camp, Stuart Donald Jones, William Alexander Wylie, John Joseph Masters, Michael Robert Wiley, Scott Martin Sheehan, David Birenbaum Engel, Brian Morgan Watson
  • Serine protease inhibitors
    Patent number: 6855715
    Abstract: Compounds of formula (I) where R2, each X, L, Y, Cy, Lp, D and n are as defined in the specification, are serine protease inhibitors useful as antithrombotic agents.
    Type: Grant
    Filed: June 13, 2000
    Date of Patent: February 15, 2005
    Assignee: Eli Lilly and Company
    Inventors: John Walter Liebeschuetz, Amanda Jane Lyons, Christopher William Murray, Andrew David Rimmer, Stephen Clinton Young, Nicholas Paul Camp, Stuart Donald Jones, Phillip John Morgan, Simon James Richards, William Alexander Wylie, John Joseph Masters, Michael Robert Wiley
  • Serine protease inhibitors
    Publication number: 20040259868
    Abstract: Compounds of formula (I) 1
    Type: Application
    Filed: July 6, 2004
    Publication date: December 23, 2004
    Inventors: John Walter Liebeschuetz, Christopher William Murray, Stephen Clinton Young, Nicholas Paul Camp, Stuart Donald Jones, William Alexander Wylie, John Joseph Masters, Michael Robert Wiley, Scott Martin Sheehan, David Birenbaum Engel, Brian Morgan Watson
  • Serine protease inhibitors
    Publication number: 20040242656
    Abstract: Compounds of formula (I) 1
    Type: Application
    Filed: June 28, 2004
    Publication date: December 2, 2004
    Inventors: John Walter Liebeschuetz, Christopher William Murray, Stephen Clinton Young, Nicholas Paul Camp, Stuart Donald Jones, William Alexander Wylie, John Joseph Masters, Michael Robert Wiley, Scott Martin Sheehan, David Birenbaum Engel, Brian Morgan Watson
  • Serine protease inhibitors
    Publication number: 20040176363
    Abstract: Compounds of formula (I) 1
    Type: Application
    Filed: March 18, 2004
    Publication date: September 9, 2004
    Inventors: John Walter Liebeschuetz, Christopher William Murray, Stephen Clinton Young, Nicholas Paul Camp, Stuart Donald Jones, William Alexander Wylie, John Joseph Masters, Michael Robert Wiley, Scott Martin Sheehan, David Birenbaum Engel, Brian Morgan Watson, Peter Robert Guzzo, Michael John Mayer
  • Serine protease inhibitors
    Patent number: 6784182
    Abstract: Compounds of formula (I) in which R2, X, Y, Cy, L and Lp(D)n have the meanings given in the specification, are inhibitors of the serine protease, factor Xa and are useful in the treatment of cardiovascular disorders.
    Type: Grant
    Filed: February 4, 2002
    Date of Patent: August 31, 2004
    Assignee: Eli Lilly and Company
    Inventors: John Walter Liebeschuetz, Christopher William Murray, Stephen Clinton Young, Nicholas Paul Camp, Stuart Donald Jones, William Alexander Wylie, John Joseph Masters, Michael Robert Wiley, Scott Martin Sheehan, David Birenbaum Engel, Brian Morgan Watson
  • Serine protease inhibitors
    Publication number: 20040142963
    Abstract: Compounds of formula (I) 1
    Type: Application
    Filed: January 12, 2004
    Publication date: July 22, 2004
    Inventors: John Walter Liebeschuetz, Christopher William Murray, Stephen Clinton Young, Nicholas Paul Camp, Stuart Donald Jones, William Alexander Wylie, John Joseph Masters, Michael Robert Wiley, Scott Martin Sheehan, David Birenbaum Engel, Brian Morgan Watson, Peter Robert Guzzo, Michael John Mayer